

Simplexa™ Influenza A H1N1 (2009) Kit
Target, identify and differentiate H1N1 in your lab
Do you want to place an order or request a trial?
Discover More
Overview
Background
While the initial threat to world health has been alleviated, H1N1 is different from other flu A viruses and may challenge health care professionals and organizations for years to come. Which is why reliable detection by molecular testing continues to be extremely important especially for higher-risk patient populations.
Why to choose it
Quickly and accurately detect and differentiate H1N1 in your lab.
For use on
Benefits
Reliable Performance
100% positive agreement for the H1N1 and influenza A virus.
Agreement with composite reference method1
2009 H1N1 Clinical Agreement
Agreement with composite reference method1 |
Swabs2 | Aspirates2 |
---|---|---|
Agreement with composite reference method1Percent Positive Agreement Percent Negative Agreement |
Swabs2100% 95.5% |
Aspirates2100% 92.5% |
Influenza A Clinical Agreement
Agreement with composite reference method1 |
Swabs2 | Aspirates2 | |
---|---|---|---|
Agreement with composite reference method1Percent Positive Agreement Percent Negative Agreement |
Swabs2100% 92.5% |
Aspirates2100% 96.1% |
|
1Specimens were determined to be positive for 2009 H1N1 influenza by a composite reference method for the Flu A target including the Luminex xTAG RVP Flu A target, a validated PCR assay using primer and probe sequences published by the CDC and a well characterized PCR followed by sequencing. 2Prospectively collected samples. 299 prospectively collected nasal/nasopharyngeal swabs and 112 nasopharyngeal aspirates were analyzed. |
Ordering info
Product | Code | Reactions |
---|---|---|
Product SimplexaTM Influenza A H1N1 (2009) Kit |
Code MOL2500 | Reactions 100 |
Do you want to place an order or request a trial?
Discover MoreOur repository
All the answers you need.
Access our database to find:
instructions for use, safety data sheets,
assay protocols and more.